Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Operating Leases (2022 - 2024)

BioXcel Therapeutics (BTAI) has 3 years of Operating Leases data on record, last reported at $65000.0 in Q4 2024.

  • For Q4 2024, Operating Leases fell 85.23% year-over-year to $65000.0; the TTM value through Dec 2024 reached $65000.0, down 85.23%, while the annual FY2024 figure was $65000.0, 85.23% down from the prior year.
  • Operating Leases reached $65000.0 in Q4 2024 per BTAI's latest filing, down from $161000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $1.0 million in Q1 2022 and bottomed at $65000.0 in Q4 2024.
  • Average Operating Leases over 3 years is $562666.7, with a median of $573000.0 recorded in 2023.
  • Peak YoY movement for Operating Leases: tumbled 31.61% in 2023, then plummeted 85.23% in 2024.
  • A 3-year view of Operating Leases shows it stood at $786000.0 in 2022, then tumbled by 44.02% to $440000.0 in 2023, then tumbled by 85.23% to $65000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $65000.0 in Q4 2024, $161000.0 in Q3 2024, and $256000.0 in Q2 2024.